Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Psychometric evaluation of the Medicare Advantage and prescription drug plan disenrollment reasons survey.

Martino SC, Elliott MN, Zaslavsky AM, Orr N, Bogart A, Ye F, Damberg CL.

Health Serv Res. 2019 Aug;54(4):930-939. doi: 10.1111/1475-6773.13160. Epub 2019 Apr 26.

PMID:
31025723
2.

Voluntary disenrollment from Medicare advantage plans: valuable signals of market performance.

Mobley LR, McCormack LA, Wang J, Squire C, Kenyon A, Lynch JT, Heller A.

Am J Manag Care. 2007 Dec;13(12):677-84.

3.

Psychometric properties of an instrument to assess Medicare beneficiaries' prescription drug plan experiences.

Martino SC, Elliott MN, Cleary PD, Kanouse DE, Brown JA, Spritzer KL, Heller A, Hays RD.

Health Care Financ Rev. 2009 Spring;30(3):41-53.

4.

Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs.

Jung K, McBean AM, Kim JA.

J Manag Care Pharm. 2012 Mar;18(2):106-15.

5.

Psychometric properties of the Consumer Assessment of Health Plans Study (CAHPS) 2.0 adult core survey.

Hargraves JL, Hays RD, Cleary PD.

Health Serv Res. 2003 Dec;38(6 Pt 1):1509-27.

6.

Medicare program; Medicare prescription drug benefit. Final rule.

Centers for Medicare & Medicaid Services (CMS), HHS.

Fed Regist. 2005 Jan 28;70(18):4193-585.

7.

Predictors of voluntary disenrollment from Medicare managed care.

Ng JH, Kasper JD, Forrest CB, Bierman AS.

Med Care. 2007 Jun;45(6):513-20.

PMID:
17515778
8.

Analysis of Drivers of Disenrollment and Plan Switching Among Medicare Advantage Beneficiaries.

Meyers DJ, Belanger E, Joyce N, McHugh J, Rahman M, Mor V.

JAMA Intern Med. 2019 Apr 1;179(4):524-532. doi: 10.1001/jamainternmed.2018.7639.

9.
10.

Medicare Prescription Drug Plan Enrollees Report Less Positive Experiences Than Their Medicare Advantage Counterparts.

Elliott MN, Landon BE, Zaslavsky AM, Edwards C, Orr N, Beckett MK, Mallett J, Cleary PD.

Health Aff (Millwood). 2016 Mar;35(3):456-63. doi: 10.1377/hlthaff.2015.0816.

PMID:
26953300
11.

Drug plan design incentives among Medicare prescription drug plans.

Huskamp HA, Keating NL, Dalton JB, Chernew ME, Newhouse JP.

Am J Manag Care. 2014 Jul;20(7):562.

12.
13.

What's Driving High Disenrollment in Medicare Advantage?

DuGoff E, Chao S.

Inquiry. 2019 Jan-Dec;56:46958019841506. doi: 10.1177/0046958019841506.

14.

Private sector unlikely to follow Medicare lead in providing health plan disenrollment comparisons.

Carman KL, Daugherty S, Harris-Kojetin LD, Lubalin JS.

Jt Comm J Qual Improv. 2002 Mar;28(3):115-26.

PMID:
11902026
15.

Medicare Advantage Ratings And Voluntary Disenrollment Among Patients With End-Stage Renal Disease.

Li Q, Trivedi AN, Galarraga O, Chernew ME, Weiner DE, Mor V.

Health Aff (Millwood). 2018 Jan;37(1):70-77. doi: 10.1377/hlthaff.2017.0974.

16.

Impact of continued biased disenrollment from the Medicare Advantage Program to fee-for-service.

Riley GF.

Medicare Medicaid Res Rev. 2012 Jan 30;2(4). pii: mmrr.002.04.a08. doi: 10.5600/mmrr.002.04.a08. eCollection 2012.

17.
18.
19.

PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.

Cline RR, Worley MM, Schondelmeyer SW, Schommer JC, Larson TA, Uden DL, Hadsall RS.

Res Social Adm Pharm. 2010 Jun;6(2):130-42. doi: 10.1016/j.sapharm.2010.04.002.

PMID:
20511112
20.

What does voluntary disenrollment from Medicare+Choice plans mean to beneficiaries?

Harris-Kojetin LD, Jaƫl EM, Smith F, Kosiak B, Brown J.

Health Care Financ Rev. 2002 Fall;24(1):117-32.

Supplemental Content

Support Center